Crispr Therapeutics AG (NASDAQ:CRSP) major shareholder Corp /De/ Celgene sold 158,718 shares of the firm’s stock in a transaction on Monday, November 20th. The stock was sold at an average price of $19.02, for a total value of $3,018,816.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Corp /De/ Celgene also recently made the following trade(s):

  • On Friday, December 1st, Corp /De/ Celgene sold 87,991 shares of Crispr Therapeutics stock. The shares were sold at an average price of $19.10, for a total value of $1,680,628.10.
  • On Wednesday, November 29th, Corp /De/ Celgene sold 4,263 shares of Crispr Therapeutics stock. The shares were sold at an average price of $19.25, for a total value of $82,062.75.
  • On Monday, November 27th, Corp /De/ Celgene sold 27,990 shares of Crispr Therapeutics stock. The shares were sold at an average price of $19.75, for a total value of $552,802.50.
  • On Friday, November 24th, Corp /De/ Celgene sold 26,010 shares of Crispr Therapeutics stock. The shares were sold at an average price of $20.00, for a total value of $520,200.00.
  • On Wednesday, November 22nd, Corp /De/ Celgene sold 256,000 shares of Crispr Therapeutics stock. The shares were sold at an average price of $19.76, for a total value of $5,058,560.00.
  • On Friday, November 17th, Corp /De/ Celgene sold 51,282 shares of Crispr Therapeutics stock. The shares were sold at an average price of $18.44, for a total value of $945,640.08.
  • On Wednesday, November 15th, Corp /De/ Celgene sold 15,000 shares of Crispr Therapeutics stock. The shares were sold at an average price of $17.67, for a total value of $265,050.00.
  • On Monday, November 13th, Corp /De/ Celgene sold 65,093 shares of Crispr Therapeutics stock. The shares were sold at an average price of $17.76, for a total value of $1,156,051.68.
  • On Friday, November 10th, Corp /De/ Celgene sold 10,000 shares of Crispr Therapeutics stock. The shares were sold at an average price of $17.28, for a total value of $172,800.00.
  • On Wednesday, November 8th, Corp /De/ Celgene sold 16,875 shares of Crispr Therapeutics stock. The shares were sold at an average price of $18.06, for a total value of $304,762.50.

Shares of Crispr Therapeutics AG (NASDAQ CRSP) traded up $0.01 during mid-day trading on Thursday, reaching $18.53. The company’s stock had a trading volume of 197,500 shares, compared to its average volume of 142,711. Crispr Therapeutics AG has a 52-week low of $11.63 and a 52-week high of $25.00.

Crispr Therapeutics (NASDAQ:CRSP) last released its earnings results on Wednesday, November 8th. The company reported ($0.62) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.02). Crispr Therapeutics had a negative net margin of 466.58% and a negative return on equity of 38.42%. The company had revenue of $2.39 million during the quarter, compared to the consensus estimate of $3.61 million. During the same period last year, the firm posted ($2.77) EPS. The company’s revenue was up 54.2% on a year-over-year basis. sell-side analysts forecast that Crispr Therapeutics AG will post -2.46 EPS for the current year.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Granahan Investment Management Inc. MA lifted its stake in shares of Crispr Therapeutics by 51.7% in the 3rd quarter. Granahan Investment Management Inc. MA now owns 263,746 shares of the company’s stock valued at $4,713,000 after acquiring an additional 89,839 shares during the last quarter. Allianz Asset Management GmbH bought a new stake in shares of Crispr Therapeutics in the 3rd quarter valued at about $2,384,000. Credit Suisse AG bought a new stake in shares of Crispr Therapeutics in the 1st quarter valued at about $1,742,000. Adams Street Partners LLC bought a new stake in shares of Crispr Therapeutics in the 3rd quarter valued at about $1,019,000. Finally, Hershey Trust Co. bought a new stake in shares of Crispr Therapeutics in the 3rd quarter valued at about $768,000. 24.55% of the stock is owned by institutional investors.

Several equities analysts have recently weighed in on the company. BidaskClub cut Crispr Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, December 2nd. Chardan Capital reiterated a “buy” rating on shares of Crispr Therapeutics in a research report on Monday, August 14th. Cann reissued a “hold” rating on shares of Crispr Therapeutics in a research note on Thursday, November 9th. SunTrust Banks reissued a “hold” rating and set a $16.00 price objective on shares of Crispr Therapeutics in a research note on Friday, November 10th. Finally, Barclays reaffirmed a “buy” rating and set a $29.00 price target on shares of Crispr Therapeutics in a research note on Friday, September 8th. Four equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $22.38.

ILLEGAL ACTIVITY NOTICE: “Corp /De/ Celgene Sells 158,718 Shares of Crispr Therapeutics AG (CRSP) Stock” was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another publication, it was stolen and reposted in violation of international trademark and copyright legislation. The correct version of this news story can be read at https://www.americanbankingnews.com/2017/12/07/corp-de-celgene-sells-158718-shares-of-crispr-therapeutics-ag-crsp-stock.html.

Crispr Therapeutics Company Profile

Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.

Insider Buying and Selling by Quarter for Crispr Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for Crispr Therapeutics AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics AG and related companies with MarketBeat.com's FREE daily email newsletter.